The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at 2-10 µg/mg of lysate.
追加情報Is unsuitable for WB.
機能Adapter protein involved in invadopodia and podosome formation and extracellular matrix degradation. Binds matrix metalloproteinases (ADAMs), NADPH oxidases (NOXs) and phosphoinositides. Acts as an organizer protein that allows NOX1-or NOX3-dependent reactive oxygen species (ROS) generation and ROS localization. Plays a role in mitotic clonal expansion during the immediate early stage of adipocyte differentiation.
組織特異性Expressed in fibroblasts.
関連疾患Defects in SH3PXD2B are the cause of Frank-Ter Haar syndrome (FTHS) [MIM:249420]. It is a syndrome characterized by brachycephaly, wide fontanels, prominent forehead, hypertelorism, prominent eyes, macrocornea with or without glaucoma, full cheeks, small chin, bowing of the long bones and flexion deformity of the fingers.
配列類似性Belongs to the SH3PXD2 family. Contains 1 PX (phox homology) domain. Contains 4 SH3 domains.
ドメインThe PX domain is required for podosome localization because of its ability to bind phosphatidylinositol 3-phosphate (PtdIns(3)P) and phosphatidylinositol 3,4-biphosphate (PtdIns(3,4)P2) and, to a lesser extent, phosphatidylinositol 4-phosphate (PtdIns(4)P), phosphatidylinositol 5-biphosphate (PtdIns(5)P), and phosphatidylinositol 3,5-biphosphate (PtdIns(3,5)P2). Binds to the third intramolecular SH3 domain.
翻訳後修飾Phosphorylated in SRC-transformed cells.
細胞内局在Cytoplasm. Cell projection > podosome. Cytoplasmic in normal cells and localizes to podosomes in SRC-transformed cells.
Detection of Human SH3PXD2B by Immunoprecipitation from HeLa whole cell lysate (1 mg for IP, 20% of IP loaded), using ab123503 at 6 µg/mg lysate for IP Subsequent Western blot detection used an antibody which recognized a downstream epitope of SH3PXD2B.
Detection: Chemiluminescence with an exposure time of 10 seconds.
Anti-SH3PXD2B antibody (ab123503) 使用論文
has not yet been referenced specifically in any publications.